1. Home
  2. CDLR vs AGIO Comparison

CDLR vs AGIO Comparison

Compare CDLR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadeler AS

CDLR

Cadeler AS

HOLD

Current Price

$25.84

Market Cap

2.0B

Sector

N/A

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$32.67

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDLR
AGIO
Founded
2008
2007
Country
Denmark
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
CDLR
AGIO
Price
$25.84
$32.67
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$39.88
AVG Volume (30 Days)
91.3K
993.4K
Earning Date
05-20-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
$51.71
$74.95
Revenue Next Year
$34.41
$165.77
P/E Ratio
$7.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.37
$22.24
52 Week High
$26.79
$46.00

Technical Indicators

Market Signals
Indicator
CDLR
AGIO
Relative Strength Index (RSI) 61.53 59.32
Support Level $19.57 $26.64
Resistance Level $26.79 $36.35
Average True Range (ATR) 0.67 1.46
MACD 0.33 0.24
Stochastic Oscillator 91.78 59.22

Price Performance

Historical Comparison
CDLR
AGIO

About CDLR Cadeler AS

Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: